PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER

Abstract: lung cancer takes the second place in the general structure of incidence of malignant neoplasms in Russia. The diagnosis of a local or metastatic non small cells lung cancer (NSCLC) serves the indication to carrying out the 1st line chemotherapy. In case of progressing against or after the...

Full description

Bibliographic Details
Main Author:	A. U. Kulikov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2015-03-01
Series:	Фармакоэкономика
Subjects:	non small cells lung cancer erlotinib pemetrexed gefitinib docetaxel «cost-effectiveness» «cost-utility»
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/35

Similar Items

Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy  in Stage IV Lung Adenocarcinoma
by: Youru LIU, et al.
Published: (2011-09-01)

The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of  Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01)

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy  for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01)

Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients
by: Yuh-Min Chen, et al.
Published: (2015-03-01)

Clinical Investigation of Efficacy of Pemetrexed in 32 Patients with Pulmonary Adenocarcinoma after Failure to Chemotherapy and Gefitinib
by: Biao WU, et al.
Published: (2010-08-01)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
by: He YY, et al.
Published: (2016-04-01)

Analisi di costo di pemetrexed vs docetaxel nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule
by: Roberto Ravasio
Published: (2005-06-01)

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
by: Minami Seigo, et al.
Published: (2012-07-01)

Gefitinib versus docetaxel in treated non-small-cell lung cancer: a meta-analysis
by: Wang Bing, et al.
Published: (2017-06-01)

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
by: Ye Jiang, et al.
Published: (2018-11-01)

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
by: Lin L, et al.
Published: (2016-10-01)

Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
by: Wang Huiyu, et al.
Published: (2019-12-01)

Maintenance therapies for non small cell lung cancer
by: Normand eBlais, et al.
Published: (2014-08-01)

Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats
by: Aliyah Almomen, et al.
Published: (2020-09-01)

Sequence-dependent Effect of Docetaxel with Gefitinib on the Proliferation  and Apoptosis of Lung Adenocarcinoma Cell H1975
by: Xinyu ZHANG, et al.
Published: (2012-03-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan
by: Thu-Lan T. Luong, et al.
Published: (2021-01-01)

Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment
by: Yang CJ, et al.
Published: (2016-03-01)

Sequence-dependent Effect of Docetaxel with Gefitinib on the Proliferation and Signal Protein Expression of Human Lung Adenocarcinoma Cell SPC-A1
by: Feng XIAO, et al.
Published: (2011-05-01)

Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1
by: Nakahara Y, et al.
Published: (2016-08-01)

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer
by: Vinzenz Kroeber, et al.
Published: (2014-07-01)

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
by: Preenumol Thomas, et al.
Published: (2019-01-01)

A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review
by: Keitaro Iida, et al.
Published: (2015-11-01)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
by: Chih-Jen Yang, et al.
Published: (2017-05-01)

Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
by: Wenxiong Zhang, et al.
Published: (2018-08-01)

The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People's Republic of China
by: Shi Q, et al.
Published: (2017-02-01)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
by: Shen Zhao, et al.
Published: (2020-11-01)

Review of EGFR TKIs in metastatic NSCLC, including ongoing trials
by: Barbara eMelosky
Published: (2014-09-01)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
by: Xin Hu, et al.
Published: (2019-12-01)

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
by: Zhang L, et al.
Published: (2021-05-01)

Personalized Prediction of Acquired Resistance to EGFR-Targeted Inhibitors Using a Pathway-Based Machine Learning Approach
by: Young Rae Kim, et al.
Published: (2019-01-01)

Synthesis of chalcone incorporated quinazoline derivatives as anticancer agents
by: Sapavat Madhavi, et al.
Published: (2017-02-01)

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
by: Wu JY, et al.
Published: (2016-10-01)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
by: Peng-Fei Zhang, et al.
Published: (2021-01-01)

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
by: Goyal Pankaj, et al.
Published: (2016-01-01)

Pemetrexed induced pneumonitis
by: Binod Dhakal, et al.
Published: (2011-11-01)

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer
by: Suzumura Tomohiro, et al.
Published: (2012-12-01)

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs
by: Jun CHEN, et al.
Published: (2010-04-01)

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
by: Murray Samuel, et al.
Published: (2012-09-01)

Cannot write session to /tmp/vufind_sessions/sess_es0qa64i1633gg5jh4qc7em7f6